This study aims to evaluate the cost-effectiveness of pemigatinib 13.5 mg per day as a second-line treatment and provide cost-effective pricing for advanced ICC with FGFR2 fusions/rearrangements compared to mFOLFOX and 5-FU from the perspective of Taiwan's NHIA by using real-world NHI claims data based on a hypothesized NHIA price for pemigatinib 13.5 mg. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.